title: Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm.
abstract: Almost 50% of serious adverse events with statin therapy are attributed to unfavorable drug-drug combinations. This article reviews updated FDA warnings on capping the dose of simvastatin, recent package insert labeling changes of particular statins that address combinations with potent cytochrome P450 inhibitors, and current renal dosing recommendations for statins.
authors.affiliation: Shannon W. Finks is an associate professor at the University of Tennessee, College of Pharmacy, Memphis, Tenn. Jennifer D. Campbell is a Clinical Pharmacist of Ambulatory Care at Regional Medical Center, Memphis, Tenn.
authors.forename: Shannon W
authors.initials: SW
authors.lastname: Finks
authors.forename: Jennifer D
authors.initials: JD
authors.lastname: Campbell
mesh_terms: D065607:Cytochrome P-450 Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D004347:Drug Interactions; D004348:Drug Labeling; D004359:Drug Therapy, Combination / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D064406:Patient Harm / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D019821:Simvastatin / Q000008:administration & dosage* / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D065607:Cytochrome P-450 Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin